The clinical efficacy of local anesthetic and antiarrhythmic drugs is due to their voltage-and frequencydependent block of Na+ channels. Quaternary local anesthetic analogs such as QX-314, which are permanently charged and membrane-impermeant, effectively block cardiac Na+ channels when applied from either side of the membrane but block neuronal Na+ channels only from the intracellular side. This difference in extracellular access to QX-314 is retained when rat brain rIlA Na+ channel a subunits and rat heart rHl Na+ channel a subunits are expressed transiently in tsA-201 cells. Amino acid residues in transmembrane segment S6 of homologous domain IV (IVS6) of Na+ channel a subunits have important effects on block by local anesthetic drugs. Although five amino acid residues in IVS6 differ between brain rIIA and cardiac rHl, exchange of these amino acid residues by sitedirected mutagenesis showed that only conversion of Thr-1755 in rHi to Val as in rIIA was sufficient to reduce the rate and extent of block by extracellular QX-314 and slow the escape of drug from closed channels after use-dependent bloclk Tetrodotoxin also reduced the rate of block by extracellular QX-314 and slowed escape of bound QX-314 via the extracellular pathway in rHl, indicating that QX-314 must move through the pore to escape.
and charged forms at physiological pH, and the uncharged form is thought to equilibrate rapidly across cell membranes allowing these drugs to block Na+ channels when applied to either the inside or outside of the membrane (10) . Because permanently charged quaternary lidocaine derivatives such as QX-314 block neuronal Na+ channels from the intracellular but not from the extracellular side, intracellular block by tertiary compounds has been interpreted to be due to tertiary drugs passing through the membrane in their uncharged form to reach an intracellular binding site (11, 12) . Recently, QX-314 was found to block native cardiac Na+ channels from the extracellular side (13) , suggesting that cardiac channels differ from neuronal Na+ channels in the molecular mechanism by which they are blocked by local anesthetic and antiarrhythmic drugs.
Amino acids in predicted transmembrane segment 6 of homologous domain IV (IVS6) of the rat brain rIIA Na+ channel play critical roles in the action of local anesthetic drugs (14) . Mutation of Phe-1764 near the center of this segment to Ala (F1764A) virtually abolished use-dependent block by disrupting the binding of local anesthetics to depolarized channels. Mutation of Ile-1760 near the extracellular end of IVS6 to Ala created a pathway by which extracellular QX-314, which is normally ineffective, could block the channel. The present study was designed to examine block of the cardiac Na+ channel by extracellular local anesthetic and antiarrhythmic drugs using QX-314 as a probe and to determine whether amino acid residues in transmembrane segment IVS6 are responsible for the difference in access of extracellular drugs to their receptor site in cardiac and brain Na+ channels.
EXPERIMENTAL PROCEDURES
Construction and Mutagenesis of rHl Na+ Channel a-Subunit cDNA. A full-length cDNA encoding the rHl Na+ channel a subunit was assembled in Bluescript SK+ by PCR amplification using primers designed from the rHl sequence (refs. 3 and 7; J.R., T.T., and W.A.C., unpublished). The plasmid pSP64T-rHl was created by insertion of the full-length rHl a-subunit cDNA into pSP64T (15) . For transient expression in mammalian cells, the rHl a-subunit cDNA was cloned into pCDM8 (Invitrogen), creating pCDM8-rHl. The plasmid pCDM8-rIIA was created by insertion of the rIIA sodium channel a-subunit cDNA (16) Hepes, pH 7.4. Pooled data are reported as mean + SEM. Statistical comparisons were made using Student's t test, and P < 0.05 was considered significant.
RESULTS
Block of Cardiac but Not Brain Na+ Channels by Extracellular QX-314. The charged, membrane-impermeant quaternary lidocaine analog QX-314 has been a valuable tool for probing mechanisms of action of local anesthetic and antiarrhythmic drugs. Consistent with previous results in nerve cells (11, 12) , exposure of cells expressing brain Na+ channels (rIIA; ref. 23) to 0.5 mM QX-314 resulted in no detectable decrease in current ( Fig. 1A and C; mean = 6% + 6%, n = 7). Exposure of four cells to concentrations up to 2 mM also produced no effect. In contrast, exposure of cells expressing cardiac Na+ channels (rH1; ref.
3) to 0.5 mM QX-314 resulted in 45% + 8% (n = 5) block of the Na+ current after 3 min of perfusion ( Fig. 1 B and D) . For three cells studied after >10 min of perfusion, block was 82% ±+ 5%, corresponding to an EC50 of 0.11 mM. Block of cardiac Na+ current by extracellularly applied QX-314 is consistent with previous results in native cardiac Purkinje fibers (13) and ventricular muscle cells (24) .
Block of Brain and Cardiac Na+ Channels by Intracellular QX-314. After achieving the whole-cell configuration, 10 min were allowed for QX-314 included in the recording pipette (200 ,uM) to diffuse into the cell. Then, a train of depolarizations (15 ms long, 1 Hz to -10 mV) was applied. Strong use-dependent block of brain and cardiac Na+ channels was observed ( Fig. 2 A and B, traces 1 and 2) . A pulse-by-pulse decrease in current was observed in cells expressing either channel (Fig. 2C ). In the absence of drug, such trains caused only 0.2% ± 2.6% (n = 3) reduction in peak current through cardiac channels (not shown). Thus, QX-314 can block brain and cardiac Na+ channels via an intracellular pathway.
Brain Na+ channels recover from block by QX-314 slowly with full recovery requiring many minutes (14) , probably reflecting trapping of the charged drug in the closed channel (9, 10, 12, 25) . To compare recovery from use-dependent block in brain and cardiac channels, a population of QX-314-blocked channels was produced using a train of depolarizations to -10 mV, and recovery at the holding potential of -140 mV was followed using infrequent short test pulses (Fig. 2 A and B , traces [3] [4] [5] . Only 9% of the current in cells expressing the brain channels recovered during the 10-min monitoring period (Fig.  2D) . In contrast, 89% of the current recovered within 5 min and recovery was virtually complete after 10 min at this holding potential for cells expressing the cardiac channels (Fig.  2D) . Thus, recovery after use-dependent block by QX-314 is far more rapid for the cardiac than for the brain channel.
Amino Acids Near the Extracellular End of IVS6 Control an Access Pathway for Extracellular QX-314. In mapping residues associated with the local anesthetic binding site, Ragsdale et al. (14) showed that mutation of Ile-1760 to Ala near the extracellular end of transmembrane helix IVS6 created an access pathway that allowed extracellularly applied QX-314 to block the channel and speeded recovery after intracellular block by QX-314. The similarity of this mutant brain channel to the native cardiac channel suggested that the differences in access of extracellular QX-314 between cardiac and brain channels might be-explained by differences in channel structure near the extracellular end of IVS6.
The amino acid sequences for the brain and cardiac Na+ channel a subunits differ from each other at five positions in transmembrane segment IVS6 (Fig. 3A) . To identify amino acids that were responsible for the different characteristics of drug block, we constructed mutant rHl channels in which these five nonconserved amino acids were changed to their To develop use-dependent block, a 1-Hz train of twenty 15-ms-long pulses to -10 mV from a holding potential of -100 mV was applied to oocytes that had been preinjected with QX-314. Recovery from use-dependent block was monitored with test depolarizations applied once every min following the end of the train. Currents were normalized as described in Fig. 2D . Each data set contains mean values ± SEM from three to seven oocytes.
brain counterparts. Consistent with the results in tsA-201 cells, expression of the WT heart and brain Na+ channels inXenopus oocytes gave rapidly and slowly recovering currents, respectively, after use-dependent block by intracellularly applied QX-314 (Fig. 3B) . The single mutations 11764V and 11772V did not significantly affect recovery of the cardiac channel from drug block (Fig. 3B) . In contrast, mutation of three amino acids clustered near the extracellular end of IVS6 to their brain counterparts (LTT1752,1755,1756FVS) caused slowed recovery from use-dependent block, a phenotype more similar to that of the brain channel. To determine the contribution of each amino acid in this triplet, cDNAs in which each of the amino acids was mutated individually were constructed. Expression inXenopus oocytes showed that one mutant, T1755V, slowed recovery from block almost as much as LTT1752, 1755,1756FVS (Fig. 3C) . In contrast, mutant L1752F had no detectable effect and T1756S had only a small effect on recovery (Fig. 3C) . These results in Xenopus oocytes were confirmed when mutants LTT1752,1755,1756FVS and T1755V were studied after transient expression in tsA-201 cells (Fig. 4A) . For both mutants, recovery from use-dependent block by QX-314 was substantially slowed in comparison to recovery in the wild-type cardiac Na+ channel.
If the slower recovery from use-dependent block in mutant channels LTT1752,1755,1756FVS and T1755V was due to occlusion of an extracellular pathway for escape of QX-314 from the channel in these mutants, block by extracellular QX-314 ought to be impeded as well. Since the drug could dissociate from the mutant channels at a measurable rate, block by extracellular QX-314 was expected to be slowed but not completely prevented. To test this possibility, 0.5 mM QX-314 was applied to the outside of tsA-201 cells expressing WT and mutant channels using a rapid perfusion system so that the rate of onset of extracellular block could be determined (Fig. 4B) . Native rHl channels were blocked rapidly. In contrast, block of mutant channels LTT1752,1755,1756FVS and T1755V was substantially slowed. The simplest interpretation of these results is that mutation T1755V impedes passage of QX-314 between the extracellular medium and its binding site, whether the drug is initially presented to the channel from the intracellular side (Fig. 4A ) or extracellular side (Fig. 4B) .
Extracellular QX-314 Approaches Its Receptor Site Through the Pore. Tetrodotoxin (TTX) is thought to block the extracellular mouth of the pore of the Na+ channel (reviewed in refs. 1 and 2) by interacting with acidic residues in the short (Fig. 6A) . In contrast, no usedependent block was observed for mutant F1762A, and 99% of the current remained after 30 pulses (Fig. 6A) . Block by extracellularly applied QX-314 was also absent in this mutant (Fig. 6B) . The finding that this single mutation inhibits block by intracellularly and extracellularly applied QX-314 suggests that drugs applied by both pathways are interacting with the same site within the transmembrane pore of the channel. To test whether the extracellular access pathway in cardiac Na+ channels required QX-314 to move through the extracellular mouth of the pore, the rates of onset and reversal of QX-314 block were measured in the presence of TTX (2 ,tM), which blocks -50% of resting cardiac Na+ channels in a rapidly reversible manner (29) . If QX-314 must pass through the outer mouth of the pore, TTX should reduce the rate of onset and reversal of QX-314 block by reducing the average fraction of Na+ channels whose drug receptor site is accessible to the extracellular medium. Consistent with this prediction, TTX reduces the rate of QX-314 block of Na+ current (Fig. SA) and the rate of reversal after use-dependent block (Fig. 5B ). Although consistent with our prediction, the amount of slowing of reversal is greater than predicted by a simple blocking model and suggests that these drugs may also interact to stabilize each other in their binding sites.
Mutation of a Single Amino Acid Prevents Block by Intracellular and Extracellular QX-314. Mutant F1764A of the rIlA brain Na+ channel a subunit dramatically reduces the sensitivity of the channel to block by local anesthetics by reducing the affinity with which they bind to the channel (14) . The equivalent mutation of the rHl a subunit, F1762A, was (9, 10, 12) , located on the intracellular side of Thr-1755 which controls drug movement between the binding site and the extracellular solution. The drug can reach this site readily from inside the cell when the channel is opened by trains of depolarizations that produce use-dependent block in rIIA and rHl Na+ channels. It can also reach this site slowly from the extracellular side of the rHl without channel opening. The finding that mutation of a single critical amino acid, Phe-1762, prevents block by intracellularly and extracellularly applied QX-314 confirms that intracellular and extracellular QX-314 interact with this single binding determinant. The simplest conclusion is that QX-314, whether applied extracellularly or intracellularly, binds at a single site containing Phe-1762. Our data are consistent with results showing that a component of block of batrachotoxin-modified cardiac Na+ channels in lipid bilayers by extracellularly and intracellularly applied lidocaine occurs at a single site but the drug arrives at that site by different access pathways (30) .
The cardiac action potential upstroke (31) and cardiac Na+ channels with intact inactivation (13) can be blocked by extracellular QX-314. Since extracellular, but not intracellular, application of QX-314 produced considerable tonic block of cardiac Na+ currents, two different blocking sites have been suggested (13) . Alternatively, these data can be explained by our proposal of a single binding site that is slowly accessible to QX-314 from the extracellular surface allowing tonic block, but that is not accessible to QX-314 from the intracellular surface until the channel is open. Block by extracellular QX-314 has not been observed after enzymatic removal of inactivation (32) or pharmacological disruption of inactivation with batrachotoxin (30) . This is consistent with our single-site model since the rate of block by extracellular QX-314 is extremely slow (Fig. 1B) , whereas reversal of block in the absence of inactivation is predicted to be rapid once the channel is opened due to escape of drug to the intracellular compartment.
Evidence for an additional drug-receptor complex was also observed in our experiments. At unphysiologically high stimulation frequencies (e.g., 20 Hz), use-dependent block by extracellularly applied QX-314 was observed in rHl and rIlA Na+ channels. Recovery from this extracellular use-dependent block was extremely rapid (<20 s for complete recovery), distinguishing it from use-dependent block by intracellular QX-314. Further experiments will be necessary to characterize the binding site responsible for this additional block and its relationship to block at more physiological frequencies of stimulation. Proc. Natl. Acad. Sci. USA 92 (1995) 11843 created a phenotype similar to that of the cardiac channel (14) . Although this residue is conserved in the rHl channel (11758), QX-314 can still block from the extracellular side. Instead, Thr-1755 seems to create the extracellular access pathway in rHl since mutation T1755V produces a brain-like phenotype in the cardiac channel. The effect of the mutation 11758A in the rHl channel is unknown since expression of this construct did not produce functional channels. Residues at positions 1755 and 1758 in the rHl a subunit primary sequence are expected to fall on the same face of the predicted IVS6 a-helix, and the residues at position 1755 in rHl and at the position analogous to 1758 in rIIA (position 1760) both influence QX-314 access to its binding site from the extracellular side. Residue F1762 controlling QX-314 affinity is also predicted to lie on the same surface of the a-helix. Because QX-314 has been shown to bind in the Na+ channel pore (33, 34) , the simplest interpretation is that residues 1755 and 1758 in rHl face the pore and affect bidirectional access of extracellular QX-314 to and from the binding site containing F1762. Consistent with that interpretation, TTX slows dissociation of QX-314 through the extracellular access pathway. Since TTX is well characterized as an extracellularly acting pore blocker (for review see ref. 29) , this result provides strong support for the idea that QX-314 moves through the pore in reaching its receptor site.
Of the amino acids in the rHl channel that differed from the rIlA isoform, only T1755V affected block by QX-314. Since this mutation was not sufficient by itself to reproduce the RIIA phenotype completely, additional differences in channel structure must be responsible for the remaining differences in phenotype. These other regions are likely to include S6 segments of homologous domains I-III as well as the predicted pore region of each homologous domain located between the S5 and S6 transmembrane segments. Further mutations in these regions will be required to account for the remaining differences in QX-314 block between the brain and cardiac isoforms.
